The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro.
Matalon
Shay
S
Department of Medicine, University of Colorado Denver, 12700 E. 19th Avenue B-168, Aurora, CO 80045, USA.
Palmer
Brent E
BE
Nold
Marcel F
MF
Furlan
Antonio
A
Kassu
Afework
A
Fossati
Gianluca
G
Mascagni
Paolo
P
Dinarello
Charles A
CA
D065100:CCR5 Receptor Antagonists; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000821:virology*; D002460:Cell Line; D002478:Cells, Cultured; D016655:HIV Core Protein p24 / Q000096:biosynthesis; D015497:HIV-1 / Q000254:growth & development*; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology*; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology*; D009000:Monocytes / Q000187:drug effects / Q000821:virology*; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors*; D014635:Valproic Acid / Q000494:pharmacology
D065100:CCR5 Receptor Antagonists; C527276:CXCR4 protein, human; D016655:HIV Core Protein p24; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D019718:Receptors, CXCR4; D014635:Valproic Acid; C502418:givinostat hydrochloride